RAIL · Project

AI Software That Reads CT Scans to Match Lung Cancer Patients With the Right Treatment

healthPilotedTRL 7

Imagine every lung tumour leaves a unique fingerprint on a CT scan — tiny patterns invisible to the naked eye. This project built software that reads those hidden patterns to predict how aggressive a cancer is and which treatment will actually work for that specific patient. Right now, about 20% of lung cancer patients get too little treatment and 30% get too much, because doctors rely on a staging system from 1958. RAIL's technology, called Radiomics, extracts hundreds of data points from standard hospital scans to give doctors a much sharper picture — no extra tests, no biopsies, just smarter use of images hospitals already take.

By the numbers

1.59 million

Annual deaths from lung cancer worldwide

EUR 18.8 billion

Economic burden of lung cancer on the EU

85%

Share of lung cancer cases that are NSCLC

20%

NSCLC patients currently under-treated

30%

NSCLC patients currently over-treated

EUR 500+ million

Potential healthcare cost reduction

The business problem

What needed solving

Lung cancer kills 1.59 million people annually and costs the EU EUR 18.8 billion, yet treatment decisions still rely on a staging system from 1958. This leads to 20% of patients being under-treated (disease progresses, patients die) and 30% being over-treated (lower quality of life, wasted healthcare spending). There is no easy, routine way to predict which treatment will actually work for a specific patient's specific tumour.

The solution

What was built

The project built and validated RadioCAP — a software tool that extracts imaging biomarkers from routine CT and PET scans to stratify lung cancer patients by tumour characteristics. Deliverables include a complete CE approval file for EU market access and completed multi-site patient accrual for clinical validation, across 12 total deliverables.

Audience

Who needs this

Hospital oncology departments struggling with treatment selection for NSCLC patientsPharma companies running expensive lung cancer clinical trials that need better patient stratificationRadiation therapy centres wanting to personalise dose and treatment plansMedical imaging software vendors looking for clinical decision support add-onsHealth insurers seeking to reduce costs from over-treatment of lung cancer patients

Business applications

Who can put this to work

Hospitals and cancer treatment centres

enterprise

Target: Oncology departments and radiation therapy clinics

If you are a hospital oncology department dealing with inconsistent treatment outcomes for lung cancer patients — this project developed a CE-marked software tool called RadioCAP that extracts imaging biomarkers from routine CT and PET scans to stratify patients more accurately. With 20% of patients currently under-treated and 30% over-treated, this tool helps match each patient to the right therapy intensity, reducing unnecessary treatments and improving survival rates.

Pharmaceutical and clinical trials

enterprise

Target: Pharma companies running oncology clinical trials

If you are a pharma company struggling with large, costly clinical trials for lung cancer drugs — this project developed imaging biomarkers that enable better patient stratification at enrolment. By selecting patients whose tumour profiles actually match the drug mechanism, trial sizes can be reduced while maintaining statistical power. The technology was validated across multiple clinical sites and published in Nature Communications.

Medical imaging software

mid-size

Target: Radiology software vendors and PACS providers

If you are a medical imaging software company looking to add clinical decision support to your platform — this project created a validated radiomics engine that plugs into existing CT and PET imaging workflows. The technology has completed CE approval documentation for EU self-regulation, making it integration-ready for diagnostic platforms serving the EUR 18.8 billion lung cancer treatment market in Europe.

Frequently asked

Quick answers

What does this software cost and how is it licensed?

The project was developed by ptTheragnostic BV (now Oncoradiomics), an SME in the Netherlands. Based on available project data, specific pricing is not disclosed. The company operates commercially via oncoradiomics.com, suggesting a software licensing or SaaS model for hospitals and clinical trial organizations.

Can this work at industrial scale across multiple hospitals?

Yes. The project objective explicitly mentions validating a 'multi-site level I imaging biomarker,' meaning it was designed and tested to work across different hospitals with different scanner equipment. The technology works on routine CT and PET scans that hospitals already perform, requiring no new hardware.

What is the IP situation and can I license this technology?

The core Radiomics technology was developed by ptTheragnostic BV, a private SME that holds the IP. The research was published in Nature Communications, but the commercial application (RadioCAP) is proprietary. Licensing inquiries would go through Oncoradiomics directly.

Does this have regulatory approval?

The project included a specific deliverable for CE approval — a complete CE file for self-regulation of RadioCAP in the EU. This indicates the product went through the CE marking process for medical device software under EU regulations.

How long before a hospital could deploy this?

Based on the project deliverables showing CE file completion and patient accrual across clinical validation sites, the technology reached deployment readiness during the project period (2015-2020). The company website at oncoradiomics.com indicates commercial availability.

How does this integrate with existing hospital systems?

The technology works with standard CT and PET imaging data that hospitals already collect as part of routine cancer diagnostics. Based on the project description, it is designed as a 'ready-to-use application' that processes existing medical images without requiring new scanning equipment or procedures.

What clinical evidence supports this?

The underlying radiomics research was published in Nature Communications. The project completed patient accrual for multi-site clinical validation. With 12 total deliverables completed during the 2015-2020 period, the evidence base covers both the science and clinical utility of the imaging biomarkers.

Consortium

Who built it

This is a single-company project — ptTheragnostic BV (now Oncoradiomics), a Dutch SME that is 100% industry and 100% SME. The solo-company structure is typical of SME Instrument Phase 2 funding, which targets individual companies with near-market innovations. For a business buyer, this means clear IP ownership with no multi-partner licensing complexity, a focused commercial entity with direct decision-making authority, and a company purpose-built around this specific technology rather than a university spin-off juggling academic priorities.

PT THERAGNOSTIC BVCoordinator · NL

How to reach the team

Coordinator is ptTheragnostic BV (Oncoradiomics) in the Netherlands. SciTransfer can facilitate a direct introduction to their business development team.

Order a report on this consortium See PT THERAGNOSTIC BV profile →

Next steps

Talk to the team behind this work.

Want to explore licensing RadioCAP for your hospital network or integrate radiomics into your clinical trial design? SciTransfer can arrange a direct introduction to the Oncoradiomics team and provide a tailored briefing on fit with your specific needs.

Order a report on this topic More in Health & Biomedical